Eli Lilly & Co. must fork over $5.2m after losing its unprecedented challenge of Canada's court system, but the entire industry will bear the brunt of the decision as pharma patents remain vulnerable to invalidity rulings.
Lilly claimed that the interpretation of patent law by Canadian courts violated the country's obligations to protect intellectual property under...





